Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Stifel Nicolaus Sticks to Its Buy Rating for Profound Medical (PRN)

Tipranks - Tipranks - Sat Mar 7, 6:46AM CST

In a report released today, Rick Wise from Stifel Nicolaus maintained a Buy rating on Profound Medical, with a price target of $12.00.

Claim 70% Off TipRanks Premium

Wise covers the Healthcare sector, focusing on stocks such as Boston Scientific, Edwards Lifesciences, and Outset Medical. According to TipRanks, Wise has an average return of -0.8% and a 48.40% success rate on recommended stocks.

Currently, the analyst consensus on Profound Medical is a Moderate Buy with an average price target of $11.99.

See Insiders’ Hot Stocks on TipRanks >>

Based on Profound Medical’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of C$5.23 million and a GAAP net loss of C$7.89 million. In comparison, last year the company earned a revenue of C$2.83 million and had a GAAP net loss of C$9.36 million

Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PRN in relation to earlier this year.

Read More on TSE:PRN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).